Haemophilia is a serious chronic disease that impairs the body's blood clotting process and can result in joint damage, pain, internal bleeding and death. The two main types of haemophilia, haemophilia A and haemophilia B, are commonly inherited genetic disorders with defects in blood clotting factors VIII and IX respectively1. Currently, most haemophilia treatments must be infused directly into the bloodstream on a frequent basis. Our scientists are exploring innovative long-acting and subcutaneous solutions, which are aimed at reducing the current treatment burden and improving clinical outcomes, and will be complemented by research into oral treatments and gene therapy.
Around 450,000 people live with
haemophilia A or B2,3
Of these people, 50% live
in constant pain4
Meet the scientist
“This is my life’s work. Period. I first worked with people with haemophilia during the AIDS epidemic in the 1980s. Today, we have recombinant products with high safety available for treatment, and we’re working on longer-acting molecules and subcutaneous treatments.”
Global Chief Medical Officer for Haemophilia,
Since 2005, the Novo Nordisk Haemophilia Foundation, a non-profit organisation, has been working to improve access to care for people with haemophilia and related bleeding disorders in the developing world. Focused on improving haemophilia diagnosis and education, the foundation supports awareness activities and the development of strategic partnerships.
We are always seeking partnerships that focus on novel targets and innovative compounds and technologies that address the unmet medical needs of people with haemophilia and other rare and serious haematological disorders. We are currently seeking to partner with academia and other pharmaceutical companies on:
To contribute to the
scientific community in our areas of expertise, we take pride in
publishing our scientists’ new findings. Visit the library to review
some of their recent work.